A Rare Case of Autoimmune Demyelinating Polyneuropathy and Hydrocephalus Secondary to Pembrolizumab

Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death 1 protein (PD-1) receptor and blocks the inhibitory checkpoint interaction between PD-1 and its ligands. This interaction leads to the upregulation of effector T-cells and downregulating regulatory T-cell product...

Full description

Saved in:
Bibliographic Details
Published inJIM - high impact case reports Vol. 8; p. 2324709620916358
Main Authors Arora, Aakriti, Shere, Amar, Patel, Kunal, Gunawardhana, Nuwan, LiFuentes, Ericka
Format Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 2020
Sage Publications Ltd
SAGE Publishing
Subjects
Case Report
Case reports
Hydrocephalus
Immunotherapy
Monoclonal antibodies
Squamous cell carcinoma
Targeted cancer therapy
immune system
pembrolizumab
AIDP
squamous cell carcinoma
Online AccessGet full text

Cover

More Information
Summary:Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death 1 protein (PD-1) receptor and blocks the inhibitory checkpoint interaction between PD-1 and its ligands. This interaction leads to the upregulation of effector T-cells and downregulating regulatory T-cell production. Although this mechanism is essential for the management of cancer, it may lead to decreased self-tolerance with an autoimmune reaction toward healthy functioning tissue. One of the less commonly reported and less understood immune-related adverse events includes neuromuscular complications. We present a rare case of autoimmune demyelinating polyneuropathy and hydrocephalus secondary to pembrolizumab use for cutaneous squamous cell carcinoma of the cheek.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:2324-7096
2324-7096
DOI:10.1177/2324709620916358